(292) The Development of Long-acting Teriparatide Formulations to Treat Osteoporosis

Introduction: Osteoporosis is a bone disease that develops when bone mineral mass or density decreases. This can lead to bone fractures. Parathyroid hormone (PTH) plays a key role in calcium homeostasis and osteoporosis. The PTH stimulates bone formation by promoting osteoblasts. A 20 micro-gram intramuscular administration of teriparatide (a PTH analog) on daily basis for 28 days is an effective treatment option. The objective of the investigation is to develop a long-acting teriparatide formulation and reduce the frequency of intramuscular administration.